Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its target price boosted by investment analysts at Wells Fargo & Company from $235.00 to $250.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has an “overweight” rating on the specialty pharmaceutical company’s stock. Wells Fargo & Company‘s target price suggests a potential upside of 32.30% from the company’s current price.

A number of other brokerages have also recently issued reports on JAZZ. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a report on Monday, December 29th. Morgan Stanley restated an “overweight” rating and issued a $225.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, January 8th. Truist Financial raised their price objective on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Wall Street Zen upgraded Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Finally, Needham & Company LLC upped their target price on Jazz Pharmaceuticals from $210.00 to $235.00 and gave the company a “buy” rating in a report on Monday, January 12th. Thirteen analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $213.85.

Jazz Pharmaceuticals Price Performance

Jazz Pharmaceuticals stock opened at $188.97 on Wednesday. The company has a market cap of $11.63 billion, a P/E ratio of -31.65, a price-to-earnings-growth ratio of 1.06 and a beta of 0.26. Jazz Pharmaceuticals has a one year low of $95.49 and a one year high of $198.00. The business has a fifty day moving average of $169.18 and a two-hundred day moving average of $150.86. The company has a debt-to-equity ratio of 1.00, a quick ratio of 1.44 and a current ratio of 1.86.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, February 24th. The specialty pharmaceutical company reported $6.64 earnings per share for the quarter, topping analysts’ consensus estimates of $6.49 by $0.15. Jazz Pharmaceuticals had a negative net margin of 8.35% and a positive return on equity of 6.87%. The business had revenue of $1.20 billion for the quarter, compared to analysts’ expectations of $1.17 billion. During the same period in the prior year, the company posted $6.51 EPS. The business’s revenue for the quarter was up 8.1% on a year-over-year basis. As a group, analysts predict that Jazz Pharmaceuticals will post 16.96 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 4,660 shares of the firm’s stock in a transaction on Friday, December 5th. The stock was sold at an average price of $171.20, for a total transaction of $797,792.00. Following the completion of the transaction, the chief accounting officer owned 7,012 shares of the company’s stock, valued at approximately $1,200,454.40. This trade represents a 39.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Mary Elizabeth Henderson sold 2,238 shares of the company’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $169.51, for a total value of $379,363.38. Following the completion of the sale, the senior vice president owned 19,508 shares in the company, valued at $3,306,801.08. This represents a 10.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 4.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Farther Finance Advisors LLC grew its holdings in shares of Jazz Pharmaceuticals by 754.8% during the third quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company’s stock worth $35,000 after buying an additional 234 shares in the last quarter. Hilltop National Bank acquired a new stake in Jazz Pharmaceuticals during the fourth quarter worth approximately $36,000. Hantz Financial Services Inc. boosted its position in Jazz Pharmaceuticals by 471.4% during the second quarter. Hantz Financial Services Inc. now owns 360 shares of the specialty pharmaceutical company’s stock worth $38,000 after acquiring an additional 297 shares during the last quarter. LRI Investments LLC purchased a new stake in Jazz Pharmaceuticals in the 4th quarter worth approximately $38,000. Finally, Danske Bank A S acquired a new position in Jazz Pharmaceuticals in the 3rd quarter valued at $40,000. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Q4 results beat: Jazz reported Q4 revenue of ~$1.20B and EPS of $6.64, topping consensus and showing year-over-year revenue growth driven by neuroscience and oncology products. JAZZ Stock Rises as Q4 Earnings & Sales Top Expectations
• Positive Sentiment: Strong oxybate/Xywav growth is a core driver of the beat and underpins management’s optimism for 2026. Jazz Pharmaceuticals beats estimates on strong Xywav growth
• Positive Sentiment: 2026 revenue outlook raised: management projects $4.25B–$4.50B for 2026 while highlighting progress on rare-disease and oncology launches — a bullish forward signal. Jazz projects 4.25B–4.50B 2026 revenue
• Positive Sentiment: Multiple analyst price-target upgrades and bullish ratings after the print (Bank of America, Wells Fargo, Morgan Stanley, RBC) lift forward sentiment and imply substantial upside from current levels. Analyst price target raises TickerReport: BofA raise
• Neutral Sentiment: Detailed context available in the earnings call transcript and investor presentation for pipeline, launch timing and margin assumptions. Investors may want to review these for items that affect long-term modeling. Earnings Call Transcript Earnings Presentation
• Negative Sentiment: Near-term pullback/volatility drivers: the stock ran up into the print (near its 52‑week high), trading volume is elevated, and some investors are likely taking profits despite the beat — a plausible reason for the intraday decline.
• Negative Sentiment: Structural/valuation considerations: Jazz still has leverage on the balance sheet and reported a negative net margin in the background data; some investors may be cautious on margins and cash flow conversion as the company invests in launches. (See earnings coverage for metrics.) Earnings Call Summary

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.